Epinephrine is under clinical development by ARS Pharmaceuticals and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData, Phase II drugs for Chronic Urticaria Or Hives have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Epinephrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine overview
Epinephrine (Neffy, Eurneffy) acts as sympathomimetic agent. It is formulated as spray for nasal route of administration. Neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.
Epinephrine (ARS-1) is under development for the treatment of anaphylaxis caused by severe allergic reactions to medications, insect bites, asthma, urticaria, food allergy. It is formulated as spray and administered through intranasal route. The drug candidate acts by targeting ADRA, ADRB adrenergic receptors. It is developed based on Intravail technology. It was also under development for seasonal allergic rhinitis and infectious rhinitis.
ARS Pharmaceuticals overview
ARS Pharmaceuticals (ARS Pharma) is a biopharmaceutical company that develops the treatments for severe allergic reactions. The company’s main product in development is a needle-free, low-dose intranasal epinephrine nasal spray intended for use as a rescue medication for people with Type 1 severe allergic reactions, including anaphylaxis. Its products include neffy. ARS Pharma’s products are designed for patients and caregivers that need a safe, effective, and easy-to-administer alternative to injectable devices. It serves customers across the US. ARS Pharma is headquartered in San Diego, California, the US.
For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
